NEUROCRINE BIOSCIENCES INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.9B | $2.4B | $1.9B | $1.5B | $1.1B |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M |
| Operating expenses | — | — | — | — | $1.0B |
| Cost of revenue | $52.1M | $34.0M | $39.7M | $23.2M | $14.3M |
| Cash from operations | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M |
| Capital expenditure | $34.0M | $38.2M | $28.3M | $16.5M | $23.4M |
| Free cash flow | $748.7M | $557.2M | $361.6M | $322.9M | $233.1M |
| Share repurchases | $167.7M | $300.0M | $0 | $0 | — |
| Total assets | $4.6B | $3.7B | $3.3B | $2.4B | $2.1B |
| Total liabilities | $1.4B | $1.1B | $1.0B | $660.9M | $698.5M |
Shares outstanding 100.5M · Free float 84.3%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.